Last ¥4,337 JPY
Change Today -81.00 / -1.83%
Volume 1.4M
As of 2:00 AM 10/2/14 All times are local (Market data is delayed by at least 15 minutes).

eisai co ltd (4523) Snapshot

Open
¥4,388
Previous Close
¥4,418
Day High
¥4,392
Day Low
¥4,324
52 Week High
09/25/14 - ¥4,510
52 Week Low
02/6/14 - ¥3,694
Market Cap
1.3T
Average Volume 10 Days
1.1M
EPS TTM
¥102.47
Shares Outstanding
296.6M
EX-Date
03/27/15
P/E TM
42.3x
Dividend
¥150.00
Dividend Yield
3.46%
Current Stock Chart for EISAI CO LTD (4523)

Related News

No related news articles were found.

eisai co ltd (4523) Related Businessweek News

No Related Businessweek News Found

eisai co ltd (4523) Details

Eisai Co., Ltd. manufactures and sells pharmaceutical products worldwide. The company offers oncology-related products, such as Halaven, an anticancer agent; Aloxi, an antiemetic agent; Dacogen, a DNA methylation inhibitor; and Fragmin, an injectable anticlotting agent, as well as Symbenda/Treakisym, a treatment for low-grade non-Hodgkin's lymphoma and other types of lymphatic cancer. It also provides Aricept, an anti-Alzheimer's agent; Pariet/AcipHex, a proton-pump inhibitor; and Humira, a human anti-TNF-a monoclonal antibody. In addition, the company offers epilepsy products comprising Zonegran, Zebinix, and Fycompa, which are antiepileptic agents; and Inovelon/BANZEL for the treatment of Lennox-Gastaut syndrome. Further, it provides Methycobal, a peripheral neuropathy treatment; Warfarin, an oral anticoagulant; Actonel, an osteoporosis treatment; Selbex for the treatment of gastritis/gastric ulcer; consumer healthcare (over-the-counter) products, which include vitamin B2 preparation Chocola BB Plus; BELVIQ, an antiobesity agent; and Stronger Neo-Minophagen C/Glycyron tablets for liver disease/allergic disease treatment. Additionally, the company is involved in the research and development of various products under the areas of oncology and supportive care, vascular and immunological reaction, gastrointestinal and hepatic disorders, and neurology. It has collaboration agreement with Biogen Idec to develop and commercialize Alzheimer's disease treatments. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.

10,419 Employees
Last Reported Date: 06/20/14
Founded in 1941

eisai co ltd (4523) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

eisai co ltd (4523) Key Developments

Eisai Co., Ltd. Submits Application in Japan for Indication Expansion of Vascular Embolization Device Dc Bead to Include Treatment of Hypervascularized Tumors and Arteriovenous Malformations

Eisai Co., Ltd. announced that it has submitted an application for the indication expansion of the vascular embolization device DC Bead for additional use in the treatment of hypervascularized tumors and arteriovenous malformations in Japan. DC Bead contains hydrophilic microspheres made from cross-linked polyvinyl alcohol polymer. Developed by Biocompatibles UK Limited as an intravascular embolization device, it is injected via catheter into targeted blood vessels to achieve selective embolization. Eisai acquired the exclusive rights to develop and market DC Bead in Japan from Biocompatibles in July 2009 and received manufacturing and marketing authorization for the device from Japan's Ministry of Health, Labour and Welfare in April 2013 for use in transcatheter arterial embolization in hepatocellular carcinomas. Eisai launched DC Bead with this indication in Japan in February 2014. A hypervascularized tumor most commonly refers to hepatocellular carcinoma, certain metastatic liver cancers, renal cell carcinoma, soft -tissue osteosarcoma, uterine fibroids and other tumors that are nourished via a sophisticated vascular network developed in tumor tissue. By selectively embolizing blood vessels to cut off the nutrient supply to the tumor tissue of these types of hypervascularized tumors, it is possible to kill or reduce them. It was recommended at the MHLW's Study Council for the Early Introduction of Highly Needed Medical Devices that DC Bead be made available as soon as possible as a device indicated for the treatment of hypervascularized tumors as well as AVM, therefore Eisai conducted clinical studies on hypervascularized tumors and AVM accordingly in Japan. Results of these studies suggested that DC Bead was highly efficient as a medical device, which has led to this application for indication expansion. Eisai positions oncology as a key franchise area. In Japan, the company currently markets the anti-cancer products of Halaven, TREAKISYM Injection 100mg as well as Gliadel 7.7 mg Implant, and in June 2014, submitted a marketing authorization application for lenvatinib mesylate for the treatment of thyroid cancer. Through this indication expansion application for DC Bead, Eisai seeks to further contribute to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer and their families as well as healthcare providers.

Eisai Co., Ltd.'s Anti-Alzheimer's Agent Aricept® Receives Approval

Eisai Co., Ltd. announced that its anti-Alzheimer's agent Aricept® (donepezil hydrochloride) has received approval for a new indication for dementia with Lewy bodies (DLB) in Japan.

Eisai Co., Ltd. to Present Latest Clinical Data on Halaven (Eribulin) and Lenvatinib at 39th European Society for Medical Oncology Congress

Eisai Co., Ltd. announced that a series of abstracts highlighting the latest clinical data on Halaven (generic name: eribulin mesylate; non-taxane microtubule dynamics inhibitor, 'Halaven') and lenvatinib mesylate (generic name; selective inhibitor of receptor tyrosine kinases (RTK's) with a novel binding mode, 'lenvatinib') will be presented during the 39th European Society for Medical Oncology (ESMO) Congress 2014, taking place in Madrid, Spain, from September 26-30. For eribulin, three abstract poster presentations including a quality of life analysis of a phase III study on metastatic breast cancer (study 301) are to be presented at the meeting. In June this year, Halaven was approved in Europe for an additional indication of locally advanced or metastatic breast cancer which has progressed after at least one chemotherapeutic regimen for advanced disease (prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments). For lenvatinib, an oral presentation highlighting an analysis of serum biomarker and tumor gene mutation associated with clinical outcomes of a Phase III study on radioiodine-refractory differentiated thyroid cancer (the SELECT (study of E 7080 LE nvatinib in differentiated C ancer of the T hyroid) study) as well as four abstract poster presentations are also scheduled to be presented at the meeting. Applications for marketing authorization approval of lenvatinib were submitted in Japan for the indication of thyroid cancer in June 2014 and in Europe and the U.S. for the indication of progressive radioiodine-refractory differentiated thyroid cancer in August 2014. Eisai positions oncology as a key franchise area. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research, and in doing so seeks to make further contributions to address the diversified needs of, and increase the benefits provided to, patients and their families as well as healthcare providers.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4523:JP ¥4,336.50 JPY -81.00

4523 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €11.21 EUR -0.27
Cubist Pharmaceuticals Inc $64.75 USD -1.59
Nektar Therapeutics $12.07 USD 0.00
Salix Pharmaceuticals Ltd $154.56 USD -1.68
Synergy Health PLC 1,438 GBp -12.00
View Industry Companies
 

Industry Analysis

4523

Industry Average

Valuation 4523 Industry Range
Price/Earnings 40.0x
Price/Sales 2.0x
Price/Book 2.3x
Price/Cash Flow 41.6x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EISAI CO LTD, please visit www.eisai.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.